Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial

Overview of attention for article published in Journal of Clinical Oncology, June 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 6 news outlets
blogs: 1 blog
policy: 1 policy source
twitter: 36 X users

facebook: 1 Facebook page
wikipedia: 1 Wikipedia page
guideline: 4 clinical guideline sources

Readers on

mendeley: 245 Mendeley

So far, Altmetric has seen 6 news stories from 6 outlets.

177Lu-Dotatate plus octreotide was not superior in overall survival compared to octreotide alone for neuroendocrine tumours | 2 Minute Medicine

2 Minute Medicine , 29 Nov 2021

1. The median overall survival for patients receiving177Lu-Dotatate and intramuscular, long-acting octreotide was 47.0 months…

Lutathera may Improve Quality of Life in Midgut Neuroendocrine Tumors

Medindia, 13 Jun 2018

Lutathera may improve the quality of life for midgut neuroendocrine tumor patients, a new study at the H.

Newly-approved therapy provides improved quality of life for midgut neuroendocrine tumour patients. ecancer

ecancer, 13 Jun 2018

Midgut neuroendocrine tumours are a rare type of cancer that develops in the small intestine and colon.

New FDA-approved therapy provides better quality of life for patients with midgut neuroendocrine tumors

The Medical News, 12 Jun 2018

Midgut neuroendocrine tumors are a rare type of cancer that develops in the small intestine and colon.

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 2 additional news stories.